KERYX BIOPHARMACEUTICALS, INC. SPECIAL NONSTATUTORY STOCK OPTION AGREEMENT
Exhibit
10.5
KERYX
BIOPHARMACEUTICALS, INC.
2007
GENERAL COUNSEL INCENTIVE STOCK OPTION PLAN
Optionee:
Xxxx
X. Xxxxxx
Number
Shares Subject to Option: 150,000
Exercise
Price per Share: $11.02
Date
of
Xxxxx: April
25, 2007
1. Grant
of Option.
Keryx
Biopharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named
above (the “Optionee”) a Non-statutory Stock Option to purchase, on the terms
and conditions set forth in this agreement (this “Option Agreement”), the number
of shares indicated above of the Company’s $0.001 par value common stock (the
“Stock”), at the exercise price per share set forth above (the “Options”).
2. Vesting
of Options.
(a) Unless
the exercisability of the Options is accelerated in accordance with this
Agreement, the Options shall vest (become exercisable) as to 150,000 shares
(the
“Options”) in accordance with the following schedule:
Months
of Employment
|
Number
of Options Vested
|
|
12
|
37,500
|
|
15
|
9,375
|
|
18
|
9,375
|
|
21
|
9,375
|
|
24
|
9,375
|
|
27
|
9,375
|
|
30
|
9,375
|
|
33
|
9,375
|
|
36
|
9,375
|
|
39
|
9,375
|
|
42
|
9,375
|
|
45
|
9,375
|
|
48
|
9,375
|
(b) Notwithstanding
the above, the Options will become immediately exercisable upon (i) the
Optionee’s termination of service by the Company without Cause, (ii) the
Optionee’s resignation for Good Reason, or (iii) upon a Change in Control (as
such terms are defined in Optionee’s Employment Agreement, dated April 25, 2007
(the “Employment Agreement”)).
3. Term
of Option and Limitations on Right to Exercise.
The
term
of the Option will be for a period of ten years, expiring at 5:00 p.m., Eastern
Time, on the tenth anniversary of the date of grant (the “Expiration Date”). To
the extent not previously exercised, the Option will lapse in accordance with
the following provisions, as applicable (but in no event later than the
Expiration Date):
(a) Three
(3)
months after the termination of Optionee’s service for any reason other than by
reason of Optionee’s (i) death, (ii) Disability, (iii) termination by the
Company without Cause, (iv) resignation by Optionee for Good Reason, or (v)
termination by the Company for Cause (as such terms are defined in
the
Employment Agreement).
(b) Twenty-four
(24) months after the date of the termination of Optionee’s service by reason of
Optionee’s (i) Disability, (ii) termination by the Company without Cause, or
(iii) resignation by Optionee for Good Reason (as such terms are defined
in
the
Employment Agreement).
(c) Twenty-four
(24) months after the date of Optionee’s death, if Optionee dies while a service
provider, or during the three-month period described in subsection (a) above
or
during the twenty-four month period described in subsection (b) above and before
the Options otherwise lapse. Upon Optionee’s death, the Options may be exercised
by Optionee’s designated beneficiary.
(d) Three
(3)
months after the date of Optionee’s termination of service by the Company for
Cause (as such term is defined in
the
Employment Agreement).
If
the
Optionee or his beneficiary exercises an Option after termination of service,
the Option may be exercised only with respect to the shares that were otherwise
vested on the Optionee’s termination of service (including vesting by
acceleration in accordance with Section 2 of this Agreement).
4. Exercise
of Option.
The
Options shall be exercised by (a) written notice directed to the Secretary
of
the Company or his or her designee at the address and in the form specified
by
the Secretary from time to time and (b) payment to the Company in full for
the
shares of Stock subject to such exercise (unless the exercise is a
broker-assisted cashless exercise, as described below). If the person exercising
an Option is not Optionee, such person shall also deliver with the notice of
exercise appropriate proof of his or her right to exercise the Option. Payment
for such shares of Stock shall be in (a) cash, (b) shares of Stock previously
acquired by the purchaser, which have been held by the purchaser for such period
of time, if any, as necessary to avoid variable accounting for the Option,
or
(c) any combination thereof, for the number of shares of Stock specified in
such
written notice. The value of surrendered shares of Stock for this purpose shall
be the Fair Market Value as of the last trading day immediately prior to the
exercise date. To the extent permitted under Regulation T of the Federal Reserve
Board, and subject to applicable securities laws and any limitations as may
be
applied from time to time by the Committee (which need not be uniform), the
Options may be exercised through a broker in a so-called “cashless exercise”
whereby the broker sells the Option shares on behalf of Optionee and delivers
cash sales proceeds to the Company in payment of the exercise price. In such
case, the date of exercise shall be deemed to be the date on which notice of
exercise is received by the Company and the exercise price shall be delivered
to
the Company by the settlement date.
5. Beneficiary
Designation.
Optionee
may, in the manner determined by the Committee, designate a beneficiary to
exercise the rights of Optionee hereunder and to receive any distribution with
respect to the Options upon Optionee’s death. A beneficiary, legal guardian,
legal representative, or other person claiming any rights hereunder is subject
to all terms and conditions of this Agreement, and to any additional
restrictions deemed necessary or appropriate by the Committee. If no beneficiary
has been designated or survives Optionee, the Options may be exercised by the
legal representative of Optionee’s estate, and payment shall be made to
Optionee’s estate. Subject to the foregoing, a beneficiary designation may be
changed or revoked by Optionee at any time provided the change or revocation
is
filed with the Company.
-2-
6. Withholding.
The
Company or any employer affiliate has the authority and the right to deduct
or
withhold, or require Optionee to remit to the employer, an amount sufficient
to
satisfy federal, state, and local taxes (including Optionee’s FICA obligation)
required by law to be withheld with respect to any taxable event arising as
a
result of the exercise of the Options. The withholding requirement may be
satisfied, in whole or in part, at the election of the Secretary, by withholding
from the Options shares of Stock having a Fair Market Value on the date of
withholding equal to the minimum amount (and not any greater amount) required
to
be withheld for tax purposes, all in accordance with such procedures as the
Secretary establishes.
7. Limitation
of Rights.
The
Options do not confer to Optionee or Optionee’s beneficiary designated pursuant
to Section 5 any rights of a shareholder of the Company unless and until shares
of Stock are in fact issued to such person in connection with the exercise
of
the Options. Nothing in this Agreement shall interfere with or limit in any
way
the right of the Company or any affiliate to terminate Optionee’s service at any
time, nor confer upon Optionee any right to continue in the service of the
Company or any affiliate.
8. Stock
Reserve.
The
Company shall at all times during the term of this Option Agreement reserve
and
keep available such number of shares of Stock as will be sufficient to satisfy
the requirements of this Option Agreement.
9. Restrictions
on Transfer and Pledge.
No
right
or interest of Optionee in the Options may be pledged, encumbered, or
hypothecated to or in favor of any party other than the Company or an affiliate,
or shall be subject to any lien, obligation, or liability of Optionee to any
other party other than the Company or an affiliate. The Options are not
assignable or transferable by Optionee other than by will or the laws of descent
and distribution or pursuant to a domestic relations order that would satisfy
Section 414(p)(1)(A) of the Code if such Section applied to an Option under
the
Agreement; provided, however, that the Committee may (but need not) permit
other
transfers. The Options may be exercised during the lifetime of Optionee only
by
Optionee or any permitted transferee.
10. Restrictions
on Issuance of Shares of Stock.
If
at any
time the Committee shall determine in its discretion, that registration, listing
or qualification of the shares of Stock covered by the Options upon any exchange
or under any foreign, federal, or local law or practice, or the consent or
approval of any governmental regulatory body, is necessary or desirable as
a
condition to the exercise of the Options, the Options may not be exercised
in
whole or in part unless and until such registration, listing, qualification,
consent or approval shall have been effected or obtained free of any conditions
not acceptable to the Committee.
11. Successors.
This
Option Agreement shall be binding upon any successor of the Company, in
accordance with the terms of this Agreement.
12. Severability.
If any
one or more of the provisions contained in this Option Agreement are invalid,
illegal or unenforceable, the other provisions of this Option Agreement will
be
construed and enforced as if the invalid, illegal or unenforceable provision
had
never been included.
-3-
13. Notice.
Notices
and communications under this Option Agreement must be in writing and either
personally delivered or sent by registered or certified United States mail,
return receipt requested, postage prepaid. Notices to the Company must be
addressed to:
Keryx
Biopharmaceuticals, Inc.
000
Xxxxxxxxx Xxxxxx
New
York,
NY 10022
Attn:
Secretary
or
any
other address designated by the Company in a written notice to the Optionee.
Notices to the Optionee will be directed to the address of the Optionee then
currently on file with the Company, or at any other address given by the
Optionee in a written notice to the Company.
14. Definitions.
“Board”
means the Board of Directors of the Company.
“Code”
means the Internal Revenue Code of 1986, as amended from time to
time,
and
includes a reference to the underlying final regulations.
“Committee”
means the Compensation Committee of the Board. The
Board
may reserve to itself any or all of the authority and responsibility of the
Committee under the Option Agreement or may act as administrator of the Option
Agreement for any and all purposes. To the extent the Board has reserved any
authority and responsibility or during any time that the Board is acting as
administrator of the Option Agreement, it shall have all the powers of the
Committee hereunder, and any reference herein to the Committee shall include
the
Board.
“Fair
Market Value”, on any date, means (i) if shares of Stock are listed on a
securities exchange or are traded over the Nasdaq National Market, the closing
sales price on such exchange or over such system on such date or, in the absence
of reported sales on such date, the closing sales price on the immediately
preceding date on which sales were reported, or (ii) if the shares of Stock
are
not listed on a securities exchange or traded over the Nasdaq National Market,
the mean between the bid and offered prices as quoted by Nasdaq for such date,
provided that if it is determined that the fair market value is not properly
reflected by such Nasdaq quotations, Fair Market Value will be determined by
such other method as the Committee determines in good faith to be
reasonable.
-4-
IN
WITNESS WHEREOF, Keryx Biopharmaceuticals, Inc., acting by and through its
duly
authorized officers, has caused this Option Agreement to be executed, and the
Optionee has executed this Option Agreement, all as of the day and year first
above written.
KERYX
BIOPHARMACEUTICALS, INC.
|
||
|
|
|
By: | /s/ Xxxxxxx X. Xxxxx | |
Name:
Xxxxxxx X. Xxxxx
Title:
Chief Executive Officer
|
||
OPTIONEE:
/s/
Xxxx X. Xxxxxx
Xxxx
X. Xxxxxx
|
-5-